"Capitalizing a Cure takes us into the struggle over accessing a medical breakthrough to investigate the power of finance over business, biomedicine, and public health. When sofosbuvir-based medicines launched in 2013, they promised a cure for millions of patients worldwide with hepatitis C. But their sticker shock-the drug was dubbed "the $1,000-a-day pill"-intensified a global debate over the pricing of new medicines. Weaving extensive historical research with insights from political economy and science and technology studies, Victor Roy demystifies an oft-missed dynamic in this debate: the reach of financialized capitalism into how medicines are made, priced, and valued. His account travels between public and private labs, Wall Street and corporate boardrooms, public health meetings and health centers to trace the ways sofosbuvir-based medicines became financial assets dominated by strategies of speculation and extraction at the expense of access and care. Provocative and sobering, this book illuminates the harmful impact of allowing financial markets to supersede democracy and human health and points to the necessary work of building more equitable futures"--
Available from: http://www.cihr-irsc. gc.ca/e/34742.html. Bernstein A. Toward effective Canadian public-private partnerships in health research. CMAJ. ... Tyers M, Brown E, Andrews DW, et al. Problems with co-funding in Canada. Science.
This book will appeal to specialists, who will find recommendations on safer materials for 3D bioprinting and ways to analyze dietary supplements for toxic contaminants, and physicians, pharmacists and non-professionals, who will learn the ...
What are the current industrial research problems and how can they be resolved in an industrial setting? This book highlights key methods that have real impact in drug discovery and facilitate delivery of drug molecules.
Das beeinträchtigte Innovationen im Produkt- und Substanzbereich. Veränderungen werden an Geschwindigkeit und Umfang zunehmen. Hier setzt die Operational Excellence ein.
The chapters in this book are written to accentuate the interdependency and synergy between drug discovery and process development disciplines to advance a new chemical entity into clinical trials and eventually to the market.
This volume details protocols on rationale design of therapeutic siRNA molecules and its encapsulation with smart vehicles to overcome the barriers to an effective administration in vivo.
Concepts and case studies in chemical biology. John Wiley & Sons, Inc.; 2014. Pai MY, et al. Drug affinity responsive target stability (DARTS) for small-molecule target identification. Methods Mol Biol. 2015;1263:287–98. Rock FL, et al.
Bringing in a new and expert editorial board, this new edition updates existing chapters and adds 35 new ones, with topics including: opioid addiction treatments, antibody and gene therapy for cancer, blood-brain barrier, HIV treatments, ...
Introducing many pharmacological advances made, the work also describes the modern theories and scientific methodologies applied to today's studies on herbal medicines and new drug development.
Documents how science has provided an astonishing array of medicines for coping with human ailments. This volume addresses industry leaders, economic influences, and the development of individual products.